Loading
MT-302 programs myeloid immune cells inside the body to recognise TROP-2-bearing cancers. It is an experimental treatment in an early clinical trial.
The 2025 ASCO correlative abstract describes intravenous mRNA-LNP delivery of an anti-TROP2 scFv/truncated-CD89 CAR, functionally active upon association with FcRgamma-expressing myeloid cells. It reports tumour and blood pharmacodynamic observations, not a comparative efficacy estimate. NCT05969041 remains recruiting in its last registry update, dated January 2024; planned enrolment is 48. The registry age does not establish current local slot availability.
mRNA lipid nanoparticles encode an anti-TROP2 CAR to engage FcRgamma-expressing myeloid cells in vivo. Connects to TROP2.
1.Intravenous lipid nanoparticles deliver messenger RNA into endogenous myeloid cells
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"MT-302" OR ABSTRACT:"MT-302") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MT-302, not a curated reading list.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/